The pharmaceutical giant, Teva Pharmaceuticals Ltd is of the view that the firm is now depending on high-risk and high-reward drugs for the purpose of overcoming their competition in the market. This new line of drugs is the stem cell treatment and it has efficient treatments for lung Cancer and Asthma.

Teva, which still largely depends on its Multiple Scleroses drug for the attainment of revenues, has more than 30 compounds lined up in the final stages of trail. These future prospects might be able to help the firm in the situation where Copaxone that is facing competition and Cephalon is their top selling drug.

Provigil, another drug by the firm for the treatment of narcolepsy might also lose its patent soon, so the firm needs to be geared up with enough backup plans.

The executives from Cephalon and Teva are of the view that they are in the process of inventing a therapy that could treat congenital heart Failure.

“Teva’s making four or five shots on goal with a very high-risk, high-reward kind of profile”, Hershkovitz said in an interview. The drug industry is crowded with new and upcoming names and brands that say they would be able to treat almost any disease. It is essential for the older firms to be able to maintain their mark in the market.